ACOD1 as a Prognostic Marker for Sepsis
Key facts
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 52 people enrolled
- Started
- 1 Oct 2025
- Ended
- 6 Feb 2026
- Type of study
- Observational
- Treatments tested
- Blood draw for lab testing.
- Record updated
- 1 May 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adult patients aged 18-90 years diagnosed with sepsis according to the Sepsis-3 criteria within 24-48 hours of ICU admission, regardless of sex or ethnicity
- Provision of written informed consent prior to enrollment
Who cannot take part
- Preexisting hematologic malignancy, prior receipt of antineoplastic radiotherapy or chemotherapy, or documented primary immunodeficiency or autoimmune disease
- Participation in any interventional clinical trial within the preceding three months or concurrent enrollment in another clinical study at the time of screening
- Age < 18 years or ≥ 90 years
- Pregnancy or lactation
- Receipt of inpatient systemic treatment for sepsis exceeding seven days following initial diagnosis
- Inability or refusal to provide written informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, with high morbidity and mortality worldwide. Reliable biomarkers are needed for early risk stratification and outcome prediction. This prospective, single-center, observational study aims to evaluate the prognostic value of Acod1 gene expression in peripheral blood mononuclear cells (PBMCs) from septic patients. The primary objective is to assess the sensitivity and specificity of ACOD1 expression measured by RT-qPCR within 24-48 hours of ICU admission for predicting sepsis mortality. Secondary objectives include correlating ACOD1 expression with the SOFA score, and comparing its predictive performance against established clinical markers and scores such as APACHE II, SOFA, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), arterial lactate, and IL-1β expression. The study will also report in-hospital mortality. Findings may support ACOD1 as a novel molecular biomarker for early prognostic assessment in sepsis.
Treatments tested
- Blood draw for lab testing.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of Acod1 in Prognostic Evaluation of Sepsis: A Prospective, Single-Center, Observational Study
- Record updated
- 1 May 2026